ZBTB2

Across TCGA pan-cancer cohorts, ZBTB2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZBTB2 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZBTB2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZBTB2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where ZBTB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.914	0.742	.006	25	view →
CCRCC	DFS	Tertile	II,III,IV	0.886	0.450	.006	18	view →
LSCC	DFS	Quartile	All	0.909	0.506	.003	7	view →
LUAD	DFS	Median	All	0.932	0.865	.034	2	view →
HNSC	DFS	Median	All	0.900	0.979	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZBTB2–PDAC (OS)

Open the PDAC breakdown →